INmune Bio, Inc.
NASDAQ:INMBBiotechnology
Healthcare
$1.89 +8.38%
+$0.15 today
- Market cap
- $50.25M
- Beta
- 0.98
- P/E (TTM)
- -1.1
- EPS (TTM)
- -$1.56
52W Low $1.09High $3.24
Volume 0.09M
Average 0.68M
Cash Flow
Check whether earnings turn into cash.
Operating Cash Flow
-$22.58M
FY 2025 · Annual
Investing Cash Flow
-$1.04M
FY 2025 · Annual
Financing Cash Flow
$27.61M
FY 2025 · Annual
+51.6% YoYCash Flow Statement
USD
Metric | FY 2021 Dec 2021 | FY 2022 Dec 2022 | FY 2023 Dec 2023 | FY 2024 Dec 2024 | FY 2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (30.34M) | (27.3M) | (30.01M) | (42.08M) | (45.93M) |
| Depreciation & Amortization | 0 | 0 | 0 | 0 | 84K |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 4.8M | 7.15M | 7.37M | 7.61M | 9.91M |
| Change in Working Capital | (3.09M) | (2.86M) | 10.44M | 1.04M | (2.53M) |
| Accounts Receivables | (3.71M) | (2.96M) | 6.02M | 1.03M | (3.13M) |
| Inventory | 3.71M | 2.96M | 0 | 0 | 0 |
| Accounts Payables | 2.26M | 1.4M | 2.72M | (1.37M) | 1.86M |
| Other Working Capital | (5.35M) | (4.27M) | 1.7M | 1.38M | (1.25M) |
| Other Non-Cash Items | 126K | 328K | 224K | 79K | 15.89M |
| Operating Cash Flow | (28.5M) | (22.69M) | (11.98M) | (33.36M) | (22.58M) |
| Capital Expenditures | (15M) | 0 | 0 | 0 | (1.04M) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | 0 | 0 | 0 | 0 | 0 |
| Investing Cash Flow | (15M) | 0 | 0 | 0 | (1.04M) |
| Debt Repayment | 14.95M | 0 | (5M) | (10M) | 0 |
| Common Stock Issued | 80.25M | 699K | 775K | 27.79M | 27.61M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 1.15M | 30K | 0 | 422K | 0 |
| Financing Cash Flow | 96.36M | 729K | (4.23M) | 18.21M | 27.61M |
| Effect of Forex Changes | (10K) | (700K) | (100K) | 224K | (159K) |
| Net Change in Cash | 52.84M | (22.66M) | (16.31M) | (14.93M) | 3.83M |
| Free Cash Flow | (43.5M) | (22.69M) | (11.98M) | (33.36M) | (23.62M) |
Free Cash Flow
Net Income to FCF bridge
FY2025
= Net Income-$45.9M
+ D&A$84.0K
+ Stock-Based Comp$9.9M
+ Deferred Tax$0
- Working Capital-$2.5M
+ Other Non-Cash$15.9M
= Operating Cash Flow-$22.6M
- Capex-$1.0M
= Free Cash Flow-$23.6M
Analysis
FY2025 free cash flow is -$23.6M. FCF conversion is 51.4% of net income. Operating cash flow was -$22.6M, with capex of -$1.0M. The largest bridge item is Other Non-Cash at $15.9M.
Competitors
Peer companies in the same sector
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| 3 | Initial statement of beneficial ownership | Sep 23, 2026 | |
| 4 | Statement of changes in beneficial ownership | Sep 23, 2026 | |
| 4 | Statement of changes in beneficial ownership | Sep 17, 2026 | |
| 3 | Initial statement of beneficial ownership | Sep 16, 2026 | |
| 8-K | Current report | Sep 14, 2026 |
Does INMB generate free cash flow?
INmune Bio, Inc. (INMB) generated -$23.62M of free cash flow in fiscal 2025.
How much operating cash flow does INMB produce?
Operating cash flow was -$22.58M, before capital expenditures of $1.04M.
Continue the stock analysis
Jump to another research area for this company.